3-吡啶异硫氰酸甲酯氢溴酸

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-吡啶异硫氰酸甲酯氢溴酸
• 英文名称: hydron;3-(isothiocyanatomethyl)pyridine;bromide
• 化学式: C7H7BrN2S
• mdl: MFCD00060721
• 分子量: 231.12
• InChiKey: KMDYQDNWXOQSOY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.58
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  57.3
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Heterocyclic modulators of nuclear receptors
  申请人：——

  公开号：US20030212111A1

  公开（公告）日：2003-11-13

  Compounds, compositions and methods for modulating the activity of nuclear receptors are provided. In particular, heterocyclic compounds are provided for modulating the activity of farnesoid X receptor (FXR), liver X receptor (LXR) and/or orphan nuclear receptors. In certain embodiments, the compounds are thiazolidinone derivatives.

  提供了用于调节核受体活性的化合物、组合物和方法。具体来说，提供了用于调节法尼索醇X受体（FXR）、肝X受体（LXR）和/或孤儿核受体活性的杂环化合物。在某些实施例中，这些化合物是噻唑啉酮衍生物。
• Novel substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators
  申请人：——

  公开号：US20030073842A1

  公开（公告）日：2003-04-17

  The invention is directed to substituted benzimidazol-2-ones of Formula I, 1 wherein A, X, Y, m, n, R 1 , R 2 , R 3 , R 4 , and R 5 are as described in the specification, which are useful as vasopressin receptor antagonists or Neuropeptide Y Modulators for treating conditions such as aggression, obsessive-compulsive disorders, hypertension, dysmenorrhea, congestive heart failure/cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, edema, ischemia, stroke, thrombosis, water retention, nephrotic syndrome, central nervous injuries, obesity, anorexia, hyperglycemia, diabetes, anxiety, depression, asthma, memory loss, sexual dysfunction, disorders of sleep and other circadian rhythms, and Cushing's disease.

  该发明涉及Formula I的取代苯并咪唑酮，其中A、X、Y、m、n、R1、R2、R3、R4和R5如说明书中所述，其可用作抗利尿素受体拮抗剂或神经肽Y调节剂，用于治疗侵略性、强迫症障碍、高血压、痛经、充血性心力衰竭/心脏不全、冠状动脉痉挛、心肌缺血、肝硬化、肾血管痉挛、肾功能衰竭、水肿、缺血、中风、血栓形成、水潴留、肾症候群、中枢神经损伤、肥胖、厌食、高血糖、糖尿病、焦虑、抑郁、哮喘、记忆丧失、性功能障碍、睡眠障碍和其他生物钟紊乱症状，以及库欣综合征。
• Heterocyclic amides having HLE inhibiting activity
  申请人：ZENECA LIMITED

  公开号：EP0509769A2

  公开（公告）日：1992-10-21

  The present invention relates to certain novel heterocyclic amides which are 1-pyridylacetamide compounds of formula I, set out herein, which are inhibitors of human leukocyte elastase (HLE), also known as human neutrophil elastase (HNE), making them useful whenever such inhibition is desired, such as for research tools in pharmacological, diagnostic and related studies and in the treatment of diseases in mammals in which HLE is implicated. The invention also includes intermediates useful in the synthesis of these heterocyclic amides, processes for preparing the heterocyclic amides, pharmaceutical compositions containing such heterocyclic amides and methods for their use.

  本发明涉及某些新型杂环酰胺，它们是式I的1-吡啶基乙酰胺化合物，载于本发明中，它们是人白细胞弹性蛋白酶（HLE），也称为人中性粒细胞弹性蛋白酶（HNE）的抑制剂，使得它们在任何需要这种抑制的情况下都有用，例如在药理学、诊断学和相关研究中用作研究工具，以及在治疗哺乳动物中涉及HLE的疾病时。本发明还包括用于合成这些杂环酰胺的中间体、制备杂环酰胺的工艺、含有这些杂环酰胺的药物组合物及其使用方法。
• NITROGENOUS HETEROCYCLIC COMPOUNDS
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1067123A1

  公开（公告）日：2001-01-10

  The present invention relates to nitrogen-containing heterocyclic compounds represented by formula (I): wherein W represents 1,4-piperazinediyl, etc.; U represents NR1R2 (wherein R1 represents a hydrogen atom, a substituted or unsubstituted alkyl group, etc.; and R2 represents a hydrogen atom, etc.), OR4, or SR5; V represents an oxygen atom, a sulfur atom, N-R6, or CR7R8, at least one of X, Y and Z represents a nitrogen atom, and the others are the same or different, and each represents a nitrogen atom or C-RA; and D1, D2, D3 and D4 each independently represent C-RB, a nitrogen atom, an oxygen atom, a sulfur atom, etc., optional adjoining two among D1 to D4 are combined to represent a nitrogen atom, N-R2A, an oxygen atom, a sulfur atom, etc., or optional adjoining two selected from D1 to D4 represent C-RB'' (wherein two RB''s are combined to represent substituted or unsubstituted alicyclic alkene, substituted or unsubstituted pyrrole, substituted or unsubstituted pyrazole, etc.; or pharmaceutically acceptable salts thereof.

  本发明涉及式（I）所代表的含氮杂环化合物： 其中 W 代表 1，4-哌嗪二基等；U 代表 NR1R2（其中 R1 代表氢原子、取代或未取代的烷基等；R2 代表氢原子等。)、OR4 或 SR5；V 代表氧原子、硫原子、N-R6 或 CR7R8，X、Y 和 Z 中至少有一个代表氮原子，其他的相同或不同，各自代表氮原子或 C-RA；D1、D2、D3 和 D4 各自独立地代表 C-RB、氮原子、氧原子、硫原子等、D1至D4中任选相邻的两个结合代表氮原子、N-R2A、氧原子、硫原子等，或任选相邻的选自D1至D4的两个代表C-RB''（其中两个RB''结合代表取代或未取代的脂环烯、取代或未取代的吡咯、取代或未取代的吡唑等）；或其药学上可接受的盐。
• SUBSTITUTED BENZIMIDAZOL-2-ONES AS VASOPRESSIN RECEPTOR ANTAGONISTS AND NEUROPEPTIDE Y MODULATORS
  申请人：Ortho-McNeil Pharmaceutical, Inc.

  公开号：EP1330451A2

  公开（公告）日：2003-07-30